{"id":63007,"date":"2026-04-13T19:56:51","date_gmt":"2026-04-13T11:56:51","guid":{"rendered":"https:\/\/flcube.com\/?p=63007"},"modified":"2026-04-13T19:56:51","modified_gmt":"2026-04-13T11:56:51","slug":"haisco-pharma-licenses-nav1-8-pain-program-to-abbvie-in-745m-deal-retaining-greater-china-rights","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63007","title":{"rendered":"Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights"},"content":{"rendered":"\n

Haisco Pharmaceutical Group Co., Ltd.<\/strong> (SHE: 002653<\/a>) has entered into a strategic exclusive licensing agreement with global biopharmaceutical leader AbbVie Inc.<\/strong> (NYSE: ABBV<\/a>) for its Nav1.8 pain program<\/strong>. The deal grants AbbVie worldwide rights (excluding Mainland China, Hong Kong, and Macau) to develop, manufacture, and commercialize two selective Nav1.8 inhibitors, HSK55718<\/strong> (IV) and HSK51155<\/strong> (oral), for pain-related indications.<\/p>\n\n\n\n

Deal Financials & Structure<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Upfront Payment<\/strong><\/td>$30 million to Haisco<\/td><\/tr>
Potential Milestones<\/strong><\/td>Up to $715 million<\/td><\/tr>
Royalties<\/strong><\/td>Tiered, based on future net sales<\/td><\/tr>
R&D Support<\/strong><\/td>AbbVie to fund costs up to clinical proof-of-concept<\/td><\/tr>
Territory<\/strong><\/td>Worldwide ex-China (Mainland, HK, Macau)<\/td><\/tr>
Assets<\/strong><\/td>HSK55718 (Phase I IV) & HSK51155 (Preclinical oral)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n